Voluntis, an innovator in advanced therapeutics, declared today its vital organization with Redox, the main interoperability stage for medical services information trade. The association will permit suppliers to computerize and adjust experiences on their patients' treatment venture inside their Electronic Health Records (EHR) to improve care and cooperation. Redox and Voluntis will cooperate with an end goal to improve the joining of advanced therapeutics as a feature of routine clinical practice and enhance EHR information with significant bits of knowledge on how patients experience their treatment at home. Clinical staff will be better prepared to foresee and actualize responsive consideration procedures that work to serve every patient's individual needs when they need it most.
“Digital therapeutics are the next disruptive force in the healthcare industry. They offer personalized therapeutic interventions for patients that are configured by their care team and backed by clinical evidence,” said Voluntis CEO Pierre Leurent. “With the collaboration of Redox, we intend to strengthen the ability of our Theraxium platform, and the digital therapeutics it supports, to work seamlessly with EHRs and be a fully integrated component of routine care.”
As a feature of the cooperation, the two organizations will incorporate Voluntis' advanced therapeutics stage, Theraxium, with Redox' interoperability stage. The new abilities will profit all the arrangements created by Voluntis along with or for its life sciences accomplices.
Today, in excess of 900 medical care associations utilizing 55 EHR merchants trust Redox to deliberately coordinate advanced wellbeing arrangements into their everyday activities. Through this association, the Voluntis arrangement of items are quickly interoperable with any association utilizing Redox for medical care information trade to advance the supplier and patient experience.
“As we navigate a challenging time in healthcare, it’s exciting to see companies like Voluntis paving the way for the future of how digital health solutions are brought to market and the extensive value they deliver,” said Niko Skievaski, co-founder and president at Redox. “Putting the power of information directly into the hands of providers and patients will help ensure actionable insights for these individuals living with chronic and rare diseases and will change the trajectory of coordinated care. We’re proud of our work with Voluntis to find more advanced ways to create a frictionless information workflow to improve care and outcomes.”
About Voluntis
Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.
About Redox
Redox accelerates the development and distribution of healthcare software solutions with a full-service integration platform to securely and efficiently exchange healthcare data. With just one connection, data can be transmitted across a growing network of 1,000 live connections in more than 900 healthcare delivery organizations and 250 independent software vendors in every state across the country. Redox regularly exchanges more than 11 million patient records per day, leveraging a single data standard compatible with more than 55 electronic health record systems.